PDXとsingel-cell Multiomeを用いたEGFR変異陽性肺癌におけるDTPとICIs不応の解明

Research Project

Project/Area Number	25K18883
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 50010:Tumor biology-related
Research Institution	Saitama Medical University
Principal Investigator	井上慶明埼玉医科大学, 医学部, 助教 (80720763)
Project Period (FY)	2025-04-01 – 2028-03-31
Project Status	Granted (Fiscal Year 2025)
Budget Amount *help	¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000) Fiscal Year 2027: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2026: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	PDX / Drug Tolerant Persister
Outline of Research at the Start	肺癌切除検体からEGFR遺伝子変異陽性細胞のPDXマウスを樹立し, EGFR-TKI投与時のDTP（Drug Tolerant Persister）細胞出現のメカニズムおよび治療中と治療前後におけるPD-L1と腫瘍微少環境をsingle cell RNA-seqを用いて明らかにする.